CD8A and neoplasm: The results suggested that CXCL9/10/11 in the tumor microenvironment may recruit CD8+ T cells and NK cells through the CXCL9–11/CXCR3 axis, thereby improving the survival of cervical cancer patients by inhibiting the development and progression of tumors.